Olympus Corp Ord (OCPNF) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Olympus Corp..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.263 -- 00:00:05.310 Hello, everyone. I am Takeuchi, Representative Executive Officer. 00:00:05.310 -- 00:00:10.636 I'd like to thank you all for participating in this conference. 00:00:13.845 -- 00:00:18.974 There were numerous challenges in FY 2025, including supply chain disruptions due 00:00:18.974 -- 00:00:24.764 to the Noto Peninsula earthquake, a difficult business environment in China, and unexpected 00:00:24.764 -- 00:00:28.206 departure of our former CEOs. 00:00:28.752 -- 00:00:33.880 Despite these headwinds, our business performance remained solid, driven 00:00:33.880 -- 00:00:39.148 by strong sales of Avis X1 GI endoscopy system in North America throughout 00:00:39.148 -- 00:00:40.790 the year. 00:00:40.790 -- 00:00:44.476 Revenue achieved close to the forecast announced in February. 00:00:44.476 -- 00:00:46.476 Adjusted 00:00:46.860 -- 00:00:52.007 operating profit was 188.5 billion yen, and adjusted operating 00:00:52.007 -- 00:00:54.668 margin was 18.9%, 00:00:54.992 -- 00:00:58.414 both exceeding the forecasts. 00:00:59.853 -- 00:01:04.898 Our quality and regulatory transformation project, Elevate, is continuing to 00:01:04.898 -- 00:01:08.322 progress well to meet our commitments to the U.S. 00:01:08.322 -- 00:01:10.322 FDA. 00:01:12.206 -- 00:01:17.412 We expect to complete all commitments to the FDA by the 00:01:17.412 -- 00:01:20.293 end of fiscal year 2026. 00:01:20.755 -- 00:01:26.782 Our three strategic guiding principles of patient safety and sustainability, 00:01:26.782 -- 00:01:32.527 innovation for growth, and productivity presented in our company strategy 00:01:32.527 -- 00:01:35.348 are progressing steadily. 00:01:35.672 -- 00:01:40.758 We made great progress with Elevate, building a solid foundation and 00:01:40.758 -- 00:...